Reactivation of fetal hemoglobin (HbF) expression using pharmacological agents represents a potential strategy for the therapy of β-thalassemia, sickle cell disease, HbE and other β-hemoglobinopathies. However, the drugs currently available have low efficacy and specificity and are associated with high toxicity. We describe the development of stable cellular genomic reporter assays (GRAs) based on the green fluorescence protein (EGFP) gene under the 
INTRODUCTION
Elevated levels of adult γ-globin chain synthesis have been shown to reduce disease severity in β-thalassemia and sickle cell disease through the formation of fetal hemoglobin (HbF, α 2 γ 2 ) or mixed hemoglobin tetramers (α 2 β S γ). Pharmacological induction of HbF is therefore being investigated as a potential therapeutic procedure in patients with β-thalassemia and sickle cell anemia.
Since the first report describing the elevation of HbF by 5-azacytidine (1), several other compounds have been found to induce HbF. Recent clinical trials using hydroxyurea have shown that it can significantly reduce the need for blood transfusion in some β-thalassemia patients, while in sickle cell anemia patients it can ameliorate the clinical symptoms and dramatically reduce the frequency of pain crisis (2) . Strong evidence in favor of a direct effect of hydroxyurea on HbF synthesis by the nitric oxide-dependent activation of soluble guanylyl cyclase has been recently reported (3) . A separate group of compounds also under evaluation are the short chain fatty acids such as butyrate and its derivatives, which have been shown to upregulate HbF in experimental in vitro models and in β-thalassemia and sickle cell anemia patients (4, 5) . As with 5-azacytidine and hydroxyurea, the level of HbF induction with butyrate has been extremely variable. Despite a number of clinical trials investigating the potential of HbF-inducing chemical agents, there are still continued concerns over the long term use of such agents. Many of these drugs have low efficacy, specificity and cytotoxicity, while some are potentially carcinogenic. There is therefore an urgent need to identify new types of pharmacological agents that can induce HbF with greater efficacy and less toxicity (6) (7) (8) .
A two-phase liquid culture assay using primary human erythroid cells has been commonly used to evaluate potential inducers of fetal hemoglobin. Measurement of γ-globin gene expression in such cultures by the RNase protection assay, globin chain biosynthesis, high-performance liquid chromatography (HPLC) and staining by γ-globin specific fluorescent antibodies have all been used to identify fetal globin gene inducers (9) (10) (11) (12) (13) , but such assays are not suitable for screening large numbers of agents. More recently, an assay based on a dual luciferase construct in murine erythroleukemia GM979 cells has been reported (14) . Simultaneous monitoring of expression of renilla luciferase, under the β-globin promoter, and of firefly luciferase, under the A γ-globin promoter, driven by a µLCR cassette in mixed stable cultures was used to examine the efficiency of various agents to preferentially induce γ-globin gene expression. A marked variability in induction was observed on different days due to the instability and heterogeneity of the mixed culture system and the lack of many endogenous regulatory sequences from the reporter construct, leading the authors to suggest that a Yeast Artificial Chromosome (YAC) based assay system may be necessary to overcome such limitations. Instability of reporter gene expression with various reporter gene constructs has also been reported in gene transfer experiments, designed to study globin gene expression (15, 16) . Host cells transduced with GFP-retroviral vectors, or stably transfected with GFP-containing plasmids carrying few, if any, of the endogenous regulatory elements, have been shown to express GFP for up to 2-4 weeks. Moreover, continuous culture often results in interrupted or variegated levels of gene expression (17, 18) . The molecular basis by which transgene expression is decreased is not totally clear, although randomly integrated minigenes are certainly subject to regulatory constraints imposed by flanking genomic sequences. In contrast, the intact β-globin locus has been shown to be isolated from such position effects and to produce regulated levels of globin gene expression in transgenic animal models (19) (20) (21) . However, difficulties in the isolation, manipulation and transfection of the intact β-globin locus have limited its use in cellular transfection studies.
We have previously generated and characterised pEBAC/148β, a eukaryotic bacterial artificial chromosome clone carrying the intact β-globin locus, and developed the GET Recombination technology for its precise experimental modification in bacterial cells (22) (23) (24) .
We have shown in transgenic studies that this genomic fragment can rescue the embryonic lethality of homozygous knockout embryos, demonstrating that it contains all the elements for regulated expression of the human γ-and β-globin genes in transgenic mice (Vadolas et al, in preparation) . We have used EGFP-modified β-globin locus constructs with the same genomic fragment to develop episomal genomic reporter assays (GRAs) in human erythroleukemia cells (25) . These episomal assays offer significant advantages for studying expression from the β-globin locus, but are not convenient for high throughput screening due to the continuous requirement for antibiotic selection, the variation in the proportion of expressing cells, the heterogeneity in the cell population with respect to episome copy number, and the likelihood of random integration of the β-globin locus construct after long periods of selection.
In this study, we describe the development of cellular GRAs that employ human erythroleukemic cells stably transfected with constructs that contain the EGFP reporter gene under the control of the G γ-globin gene promoter in the human β-globin locus. We demonstrate with these GRAs that hemin is a potent inducer of EGFP expression driven by the G γ promoter and that the induction parallels that of endogenous globin chain synthesis, resulting in the accumulation of EGFP to 5-10% of the total cellular protein. We compared the EGFP-induction potency of a number of chemotherapeutic agents, which include histone deacetylase (HDAC) inhibitors, and DNA-binding agents. We demonstrate a direct effect of hydroxyurea on γ-globin synthesis, which is comparable to butyrate, and an additive effect when both agents are used. Among the DNA-binding agents tested, cisplatin was found to be the most potent inducer of EGFP, approaching a level that is comparable to hemin induction.
We propose that these GRAs represent sensitive and physiologically relevant assays for the screening and initial evaluation of γ-globin gene inducers that should greatly facilitate a rational approach to drug design and development for the treatment of β-hemoglobinopathies. 7 The accumulation of EGFP to 5-10% of the total cellular protein also indicates that this approach may be very useful for the high level production of recombinant proteins in human erythroid cells.
RESULTS

Generation and characterisation of stable KEB clones
Under normal growth conditions, K562 cells express low amounts of ε-globin and γ-globin.
Hemin, as well as a variety of other compounds induce erythroid differentiation, which results in a sharp increase in embryonic and fetal globin gene expression (26) (27) (28) . Hence this cell line has been investigated as an in vitro model system to study globin gene regulation and to identify and evaluate γ-globin inducers (29) (30) (31) . The advantages and limitations of this cell line for the screening and evaluation of HbF inducers have been previously reviewed (25, 32) .
We previously reported that transient transfection studies in K562 cells with 21 kb (pEBAC160G) and 205 kb (pEBAC/148βG) vectors yielded low levels of transfection (4% and 0.5% respectively) (25) , imposing serious limitations on functional studies with the intact β-globin locus. To overcome these limitations KEB cell lines were generated by transfecting an EBNA1/Neo expression cassette into K562 cells (33) , since previous studies have reported up to 100-fold increase in the transfection efficiency of oriP-containing plasmids with EBNA1 expression (34) . Twenty two out of 30 KEB clones appeared to be homogeneous for EBNA1 expression by FACS analysis after limiting cell dilution. In agreeme nt with previous studies, an increased transfection efficiency was noted with all KEB clones using the 21 kb pEBAC160G vector, but there was only a weak correlation between the level of EBNA1 expression and the percentage of EGFP expressing cells (data not shown), indicating that low levels of EBNA1 expression are sufficient to facilitate increased transfection efficiency. A single KEB clone, denoted as 8.13, which displayed moderate levels of EBNA1 expression and high transfectability with pEBAC160G, was chosen for further studies.
Generation of stable KEB cell lines expressing EGFP-modified β -globin locus constructs
We could not generate K562 cells stably transfected with the EGFP-modified β-globin locus constructs, due to the very poor transfection efficiency of large genomic fragments in K562 cells. In contrast, transfection of KEB cells with linearised EGFP-modified β-globin genomic fragments followed by hygromycin selection readily led to the isolation of stable EGFP expressing clones. Since the hygromycin resistance gene and the oriP element are located on the vector backbone that was physically separated from the genomic insert in these transfection studies, it is presumed that transfection with the genomic insert was facilitated by its compaction and co-transfection with the vector backbone. However, EBNA1 has also been reported to increase reporter gene expression by affecting other intranuclear mechanisms (34) , indicating that the increased efficiency for generating stable clones with the β-globin locus fragment in KEB cells may result not only from enhanced nuclear uptake, but also from effects on other intranuclear processes.
The EGFP expressing clones were isolated by limiting cell dilution in 96-well plates following 2-3 weeks culture in the absence of drug selection. Several independent clones expressing EGFP were selected for both the pEBAC/148β:: (Table 1) . Independent clones exhibited a range of EGFP expression profiles, with differences both in the proportion of EGFP-expressing cells, as well as in the basal median peak fluorescence (MPF) of the expressing cells (Fig 2, Table 1 ). About 50% of the clones had >95% expressing cells that Table 1) .
Stability of EGFP expression in β -globin genomic reporter assays
Initial studies indicated stability and uniformity in MPF of all clone isolates for at least one month of continuous culture (data not shown). To further extend these studies the two stable cell lines established with the pEBAC/148β::
globin genomic reporter constructs were monitored by flow cytometry during exponential growth in the absence of antibiotic selection (Fig 3) . It should be noted that the basal MPF for both clones under these conditions was at least 2-fold higher than under our standard hemin induction conditions (Table 1 ). This may reflect the turnover of EGFP while slowing down protein synthesis by the fifth day of the hemin induction protocol, in comparison to high levels of fresh protein synthesis in exponentially growing cells. (Fig 3) and to undetectable levels by day 190 (data not shown). This decline was not associated with a reduction in viability or in the MPF of the expressing cells and was also accompanied by loss of hygromycin resistance, indicating non-specific chromosomal loss as the most likely mechanism for the "silencing" of EGFP expression in this culture. Stocks of both cell lines from earlier passages can thus be grown and expanded for long periods with a high level of stability and uniformity in reporter gene expression, a feature that should greatly facilitate their use in high throughput screening for novel HbF inducers.
Induction of EGFP expression in the G
γ-EGFP GRAs parallels the induction of the endogenous globin genes
Unlike small plasmid reporter constructs used by other workers to study globin gene expression and to develop screening assays (14) , the G γ-EGFP genomic reporter constructs used in this study were designed to maintain the integrity of the LCR and all other regulatory elements in the β-globin locus upstream of the G γ-globin start codon (Fig 1) . EGFP expression from these constructs in stable cell lines should therefore reflect the endogenous activity of the G γ-globin genes. In order to examine this possibility, total cellular proteins from K562, KEB and KEB- reaching a maximum 764±145% increase with hemin at 100 µM after 5 days (Fig 5) . This increase is generally in line with the increase in EGFP expression seen directly by protein analysis (Fig 4) and is quantitatively and qualitatively in general accordance with the reported increase in the expression of the γ-globin genes that occurs in K562 cells following hemin induction (26) (27) (28) .
We further investigated the respons iveness of the G γ-A γ EGFP cell line to hydroxyurea (0-100 µM) or butyrate (0-1000 µM) for up to 5 days. As with hemin, we noted a significant dose-dependent shift in the MPF of EGFP-expressing cells following induction (Fig 5) .
Maximum induction (75±10%) with hydroxyurea was observed at the highest dose tested (100 µM) after five days of induction. Similarly, maximal induction with butyrate (82±30%) was observed after five days with the highest dose tested (1000 µM). Interestingly, combination of hydroxyurea and butyrate at the highest doses tested (100/1000 µM) for five days resulted in 159±72% increase in MPF, indicating an additive effect between these agents. Very similar results were also obtained using an early passage stock of the (Table 2) . At concentrations with maximum activity, HDAC inhibitors such as α methylhydrocinnamic acid, sodium-2,2-dimethylbutyrate (36) and trichostatin A (37) were found to be relatively weak inducers, (2-24% increase in MPF), whereas apicidin (38), a recently described γ-globin inducer, increased MPF (66±11%) to levels comparable with butyrate and hydroxyurea.
We also compared the EGFP-induction potency of three commonly used chemotherapeutic agents carboplatin, cisplatin and mithramycin, which have previously been reported to induce γ-globin (29, 39) . We noted that carboplatin and mithramycin displayed similar levels of induction (42±2% and 38±7% respectively) when used at concentrations with maximum activity (Fig 6, Table 2 ). In contrast, cisplatin induced a dramatic increase in EGFP expression (442±32%), which is comparable to hemin induction (764±32%).
Discussion
Many studies focusing on the development of assays to evaluate HbF inducers have utilised small plasmid constructs with minimal regulatory elements from the β-globin locus. However, removal of the globin genes from their natural control elements, followed by random chromosomal integration, usually leads to poor and variegated transgene expression, often followed by transcriptional silencing. These events are usually the result of positional effects influenced by the site of chromosomal integration (40) (41) (42) . Attempts to overcome positional effects have focused on the inclusion of LCR elements since a number of studies with the intact genomic β-globin locus indicate that it is less susceptible to positional effects and also more likely to give physiologically relevant responses. However, limitations in the genetic engineering and low transfection efficiencies have limited until now the development of reporter assays with the intact β-globin locus. To the best of our knowledge, this is the first report utilising a fully functional β-globin locus for the development of stable genomic reporter assays in an erythroleukemia cell line.
We have observed a remarkable stability and uniformity in EGFP expression with our cellular GRAs (Fig 3) , extending to over 230 days of continuous culture with the This study examines for the first time, in a side-by-side comparison, the relative capacity of several previously described HbF inducers to specifically activate γ-globin gene expression in a human erythroid cell line. Hemin reproducibly induced a strong, dose-dependent increase in MPF (764±145%) ( Table 2) , and was used as an internal control in different experiments.
In contrast, butyrate and hydroxyurea each induced only a 70-80% increase at the highest concentrations used, but had an additive effect (159±72%). This additive effect is in line with previous clinical trials in primates and in a few patients (43, 44) , confirming that they act through different mechanisms. Mechanistically, butyrate has been shown to inhibit histone deacetylase (45) , thus affecting nucleosome stability, chromatin structure and histone binding to DNA (46, 47) . Such pleiotropic effects appear to be important in the transcriptional regulation of genes in general (31, 46) . As far as hydroxyurea is concerned, it irreversibly inhibits DNA synthesis in rapidly dividing cells by inhibiting ribonucleotide reductase, an enzyme required for DNA synthesis (48, 49) . However, the induction of γ-globin synthesis by hydroxyurea appears to be the direct effect of the nitric oxide-dependent activation of soluble guanylyl cyclase (3).
Several research efforts have been directed towards the development and identification of new γ-globin inducers, in particular towards butyrate derivatives and novel HDAC inhibitors.
We compared the EGFP-induction potency of a number of HDAC inhibitors (Table 2) . At concentrations with maximum activity, HDAC inhibitors such as α methylhydrocinnamic acid, sodium-2,2-dimethylbutyrate and trichostatin A were found to be relatively weak inducers. Thus the reported increase in HbF by these agents may not be primarily at the level of γ-globin gene transcription, a result which is consistent with the more generalised effects of α methylhydrocinnamic acid and sodium-2,2-dimethylbutyrate (36) . Apicidin has also been reported to be a more potent inducer of HbF expression than butyrate (38) . However, in our assay apicidin increased EGFP expression to a level comparable with butyrate and hydroxyurea, suggesting that it may also act through other mechanism(s).
One of the most interesting classes of chemotherapeutic agents which have recently been the subject of a number of in vitro studies, are the DNA-binding agents cisplatin, and carboplatin. The platinum atom of these compounds forms intrastrand covalent linkages at neighbouring guanine bases through the N7 position of guanine. Such DNA-binding drugs display sequence specificity and are able to interfere with the DNA-binding activity of transcription factors. Enhanced reactivity of cisplatin at a CACC site in the ε-globin promoter in K562 cells was recently demonstrated (50) , a site where FKLF, a member of the Sp1 transcription factor family of proteins, is thought to bind (51) . In this study, we found that carboplatin induced low levels of EGFP expression (43±8%), while cisplatin resulted in a level of induction (442±32%), which is comparable to hemin (764±145%) (Fig 6, Table 2 ).
Our observations are in line with a report that carboplatin and cisplatin induce the expression of γ-globin and the erythroid differentiation of K562 cells, although no significant difference between the two agents was observed by measuring the number of benzidine positive cells (29) . In this context it is important to note that cisplatin and carboplatin form identical bifunctional adducts, but the relative frequency of individual platinum-DNA cross-links and pharmacokinetic properties are quite different (52) (53) (54) . This difference, together with the enhanced sensitivity and specificity of our assay compared to benzidine staining (29) , may explain the large difference between the EGFP-inducing potential of cisplatin versus carboplatin. These results indicate that our assay may be used to study disruption of specific interactions between transcription factors and sequences on the β-globin locus with DNAbinding agents, as the first step to a rational drug design approach for the targeted disruption of such interactions by agents that modify the proteins involved rather than the DNA, thus improving the efficacy and reducing the toxicity of HbF inducers. 
MATERIALS AND METHODS
Construction of genomic reporter constructs
The P1-derived artificial chromosome (PAC) clone (148O22) was identified from the RPCI I PAC library (http://www.chori.org/bacpac/) to contain the β-globin locus (22) . Sequencing of the T7 and Sp6 ends of the genomic insert and alignment with the human genome sequence (GenBank Accession number NT_028310.10) revealed that the genomic insert is 183,039 bp long, with 122,076 bp upstream of the start codon of the ε-globin gene and 17672 bp downstream of the stop codon of the β-globin gene. However, these sequence assignments are approximate, since this clone could have large numbers of polymorphisms and other sequence variations from the published genome sequence. The 183 kb genomic fragment was retrofitted into the pEBAC140 cloning vector as a single NotI fragment to generate pEBAC/148β (Fig 1,   also referred to as pBH148β (55, 56) ). The construction of the pEBAC/148β:: (Fig 1) has been previously described (24, 25) . The start codon of the EGFP gene was targeted in frame with the start codon of the 
Preparation of pEBAC vectors
The pEBAC vectors were propagated in the E. coli strain DH10B (Invitrogen, Carlsbad, CA).
Bacterial cultures were routinely grown in LB liquid culture, or on LB agar plates (15 g/l) containing the following antibiotics as indicated in the text: 12.5 µg/ml chloramphenicol (Cm), or 25 µg/ml kanamycin (Km). Large-scale preparation of pEBAC constructs for transfection studies was performed using CsCl -ethidium bromide density gradient centrifugation.
Generation and characterisation of KEB cell lines
The generation of stable K562 cells that constitutively express EBNA1 (KEB cells) has previously been reported (25) . All KEB clones tested positive for the presence of the EBNA1 gene by PCR (data not shown). The EBNA1-specific rat MAb 1H4 (57) was used to quantitate the level of EBNA1 protein expression in each clone, using a phycoerythrin polyclonal anti-rat Ig (BD PharMingen, Los Angeles, CA.) by measuring the median peak fluorescence (MPF) by flow cytometry using a FACScan flow cytometer (BD PharMingen, Los Angeles, CA). KEB cells and derivative cell lines were maintained in continuous culture in Dulbecco's modified Eagles medium (Sigma, St Louis, MO) suppleme nted with 10% fetal calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin.
Transfection of EGFP-modified pEBAC vectors into KEB cells
The pEBAC/148β:: 
Treatment of cells with inducers of globin gene expression
Hemin (Sigma, St Louis, MO) (5 mM stock solution) was prepared as previously described Figure 1 Vadolas et al Figure 3 Vadolas et al Figure 5 Vadolas et al Figure 6 
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